

Triple E probes

the first cascading activity-based probes for ubiquitin and ubiquitin-like protein E1-E2-E3 enzyme cascades

Here we present our *Triple E* probe design (Ub-Dha, Figure 1), which to our knowledge represents the first type of cascading activity-based probe for E1-E2-E3 enzymes.^[1]

The post-translational modification of proteins with ubiquitin (Ub) and ubiquitin-like proteins (Ubls) is orchestrated by a cascade of E1, E2 and E3 enzymes. To study these enzymes, several activity-based probes (ABPs) have been developed.^[2] However, these ABPs are based on the Ub-AMP intermediate (Figure 1) and thus only target the initial E1 activity directly.

Akin to native Ub/Ubls, the ATP-dependent activation of the *Triple E* probe by E1 (Fig. 2) and sequential native trans-thioesterifications allow the probe to travel downstream to the E2 and E3. However, unlike the native Ub/Ubl, at each step along the cascade, the Dha probe can react irreversibly with an active site cysteine residue. Thus our probe 'hops' and 'traps' catalytically active E1, E2 and (HECT/RBR) E3 enzymes (Fig. 1). Our founder methodology can be used for activity-based protein profiling (ABPP) using SDS-PAGE (Fig. 3), structural studies (Fig. 4), ABPP in living cells (Fig. 6) and proteomics (Fig. 5). Overall, our *Triple E* probes represent the first tools of their kind that allow the monitoring of full E1-E2-E3 cascade activity.

Figure 1 – mechanism-based inactivation of E1-E2-E3 cascade by *Triple E* probes.




Fig. 2 – E1 labeling by Ub-Dha is ATP dependent




Fig. 3 – activity-based protein profiling with Cy5-Ub-Dha (in-gel fluorescence imaging).




Fig. 4 – structural analysis [Ub-Dha-UBE2D3] conjugate (formed via Ub E1)




Fig. 5 – proteome-wide activity profiling of Ub ligation in HeLa cells





Fig. 6A – distribution of Cy5-Ub-Dha (magenta) in HeLa cells that ectopically express GFP-UBE1 (green) relative to untransfected cells.



Monique P.C. Mulder,^{2,*} Katharina Witting,^{2,*} Ilana Berlin,^{2,*} Jonathan N. Pruneda,³ Kuen-Phon Wu,⁴ Jer-Gung Chang,⁵ Remco Merx,² Johanna Bialas,⁷ Marcus Groettrup,⁷ Alfred C.O. Vertegaal,⁶ Brenda A. Schulman,^{4,5} David Komander,³ Jacques Neefjes,² Boris Rodenko,¹ Alessia Amore,¹ Lara Krooshof,¹ Alfred Nijkerk,¹ Farid El Oualid,^{1,2*} Huib Ovaa,^{2,*}

(1) UbiQ Bio BV, Science Park 408, 1098 XH Amsterdam, The Netherlands. (2) Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. (3) MRC Lab. of Mol. Biology, Cambridge, CB2 0QH, UK. (4) St. Jude Children's Research Hospital, TN 38105, USA. (5) Howard Hughes Medical Institute, Memphis, TN 38105, USA. (6) Leiden Univ. Med. Center, 2333 ZA Leiden, the Netherlands. (7) Univ. of Konstanz, Konstanz, Germany. # = shared 1st authorship * = corresponding authors

Fig. 6B – visualizing E2 activity in HeLa cells with (electroporated) Cy5-Ub-Dha





Fig. 7 – *Triple E* probes are not transferred to substrates



take home messages

- *Triple E* probe: the first cascading activity-based probe for E1-E2-E3 pathways
- probe reactivity is ATP-dependent (Fig. 2)
- probe is not transferred to substrates (Fig. 7)
- probe has relatively low reactivity with Ub/Ubl proteases (data not shown)
- thioether linked Ub(l)-Dha-E2 conjugates act as stable (competitive) inhibitors of RING type E3 ligases (data not shown)

applications *Triple E* probe

- gel based activity-based protein profiling (Fig. 3)
- structural biology (Fig. 4)
- proteomics (Fig. 5)
- activity-based protein profiling in living cells (Fig. 6)

drug discovery

- we are currently using the mode of action of our (proprietary) *Triple E* probe^[2b] for the development of mechanism-based small molecule inhibitors of E1-E2-E3 cascades.

References. [1] (a) Mulder et al., *Nat. Chem. Biol.* 2016, *In press*. (b) MPC Mulder, F. El Oualid and H. Ovaa. *Adenylation enzyme inhibitors*. Patent pending (filed 26 Aug 2014). [2] (a) Lu et al. *J. Am. Chem. Soc.* 2010, 132, 1748. (b) Olsen et al. *Nature*, 2010, 463, 906. (c) H. An and A.V. Statsyuk, *J. Am. Chem. Soc.* 2013, 135, 16948. (d) H. An and A.V. Statsyuk *Chem. Comm.* 2016, 52, 2477. [3] Page et al. *Biochemistry* 2012, 51, 4175.